The Role of Radiotherapy in Intracranial Hemangiopericytoma/Solitary Fibrous Tumors: a Turkish Society for Radiation Oncology Central Nervous System Tumors Group Study (trod 07-008)

dc.authorscopusid 56491238500
dc.authorscopusid 14626912500
dc.authorscopusid 8894510900
dc.authorscopusid 6508205483
dc.authorscopusid 46461007800
dc.authorscopusid 23566732800
dc.authorscopusid 16303226100
dc.contributor.author Kaydıhan, N.
dc.contributor.author Yazıcı, G.
dc.contributor.author Erpolat, P.
dc.contributor.author Kamer, S.
dc.contributor.author Erdemci, B.
dc.contributor.author Canyılmaz, E.
dc.contributor.author Güney, Y.
dc.date.accessioned 2025-01-15T21:48:29Z
dc.date.available 2025-01-15T21:48:29Z
dc.date.issued 2024
dc.department Okan University en_US
dc.department-temp Kaydıhan N., Department of Radiation Oncology, Memorial Bahçelievler Hospital, İstanbul, Turkey, Faculty of Medicine, Department of Radiation Oncology, İstanbul Arel University, İstanbul, Turkey; Yazıcı G., Faculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey; Erpolat P., Faculty of Medicine, Department of Radiation Oncology, Gazi University, Ankara, Turkey; Kamer S., Faculty of Medicine, Department of Radiation Oncology, Ege University, İzmir, Turkey; Erdemci B., Faculty of Medicine, Department of Radiation Oncology, Atatürk University, Erzurum, Turkey; Canyılmaz E., Faculty of Medicine, Department of Radiation Oncology, Karadeniz Technical University, Trabzon, Turkey; Atasoy B.M., Department of Radiation Oncology, Marmara University School of Medicine, İstanbul, Turkey; Aslan D., Faculty of Medicine, Department of Radiation Oncology, Erciyes University, Kayseri, Turkey; Delikgöz Soykut E., Department of Radiation Oncology, Samsun Education and Research Hospital, Samsun, Turkey; Özyar E., Faculty of Medicine, Department of Radiation Oncology, Mehmet Ali Aydınlar Acıbadem University, İstanbul, Turkey; Demircioğlu F., Faculty of Medicine, Department of Radiation Oncology, Okan University, İstanbul, Turkey; Öner Dinçbaş F., Department of Radiation Oncology, Memorial Bahçelievler Hospital, İstanbul, Turkey, Cerrahpaşa Medical Faculty, Department of Radiation Oncology, İstanbul University-Cerrahpaşa, İstanbul, Turkey; Kirli Bolukbas M., Department of Radiation Oncology, Bakırköy Dr. Sadi Konuk Education and Research Hospital, İstanbul, Turkey; Aksu R., Department of Radiation Oncology, Diyarbakır Gazi Yaşargil Education and Research Hospital, Diyarbakır, Turkey; Tabak Dinçer S., Department of Radiation Oncology, İstanbul Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey; Bölükbaşı Y., Faculty of Medicine, Department of Radiation Oncology, Koç University, İstanbul, Turkey; Güney Y., Department of Radiation Oncology, Ankara Etlik City Hospital, Ankara, Turkey en_US
dc.description.abstract Objective: Intracranial hemangiopericytomas (HPC) are rare tumors. Radiotherapy (RT) is frequently performed after surgery, depending on tumor size, location, and the type of resection. Moreover, RT is preferred as an effective treatment for local recurrence and metastasis. With this multicenter study, we aimed to investigate the effectiveness of postoperative RT in intracranial HPC patients using modern RT techniques. Materials and methods: Patients aged 16 years and older who underwent RT for histologically confirmed intracranial HPC were evaluated retrospectively. Forty-four patients from 17 institutions were included. Demographic characteristics of the patients, pathological findings, and prognostic factors were documented. The Kaplan–Meier method was used for local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS). The interval for survival analyses was calculated according to the end date of RT. Univariate and multivariate analysis methods were used for factors associated with survival and recurrence. Results: Median age was 42 years (16–71) and 70% of the patients were male. The most common initial symptoms were pain (47.7%) and vision problems (15.9%). A supratentorial location was observed in 79.5% of patients. The median maximum tumor dimension was 4.7 (1.6–14) cm. Gross total (GTR) and subtotal resection (STR) were performed in 43.2% and 47.7% of patients, respectively. Adjuvant RT commenced a median of 6 (2–16) weeks after surgery. Postoperative RT was administered using conventionally fractionated intensity-modulated radiotherapy (IMRT) or stereotactic radiosurgery (SRS). A total median dose of 60 (38–66) Gy in a median of 30 (19–33) fractions was used for patients treated with IMRT and a total median dose of 24 (12–25) Gy in a median of 3 (1–5) fractions was used for patients treated with SRS. Local recurrence occurred in 9 patients and locoregional recurrence in 2 patients at a median of 48 months (range 26–143 months) after RT. Reoperation and reirradiation were applied to 5 patients, reirradiation to 4 patients, and reoperation to 2 patients as salvage treatments. Reirradiation was administered at a median dose of 35 (13.5–54) Gy using a median of 5 (1–30) fractions. At a median follow-up of 63 (6–262) months, 5‑year LC was 68.7%, DMFS 87.2%, PFS 60.8%, and OS 95.7%. The presence of residual macroscopic tumor before RT was associated with lower LC (p = 0.01) and shorter PFS (p = 0.04). In the presence of residual tumor before RT, 5‑year LC decreased from 92.9% to 46.7%, while 5‑year PFS decreased from 81.1% to 43.5% compared to patients with GTR. The presence of postoperative tumor was associated with a lower LC rate in Cox regression analyzes (p = 0.02). The hazard ratio was 6.2 (1.2–30). However, the effect of residual disease before RT on OS was not statistically significant. Conclusion: Adjuvant radiotherapy is performed in the majority of patients with HPC, especially in cases where GTR cannot be performed. In our study, postoperative macroscopic residual tumor was found to be the only factor affecting LC and PFS in patients undergoing adjuvant RT, but its effect on OS was not shown. This may be due to the effectiveness of reoperation and/or reirradiation in the presence of recurrence after RT. © Springer-Verlag GmbH Germany, part of Springer Nature 2024. en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.1007/s00066-024-02338-z
dc.identifier.issn 0179-7158
dc.identifier.scopus 2-s2.0-85212425729
dc.identifier.scopusquality Q2
dc.identifier.uri https://doi.org/10.1007/s00066-024-02338-z
dc.identifier.uri https://hdl.handle.net/20.500.14517/7603
dc.identifier.wosquality Q2
dc.language.iso en en_US
dc.publisher Springer Science and Business Media Deutschland GmbH en_US
dc.relation.ispartof Strahlentherapie und Onkologie en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.scopus.citedbyCount 0
dc.subject Adjuvant en_US
dc.subject Hemangiopericytoma en_US
dc.subject Intracranial en_US
dc.subject Radiotherapy en_US
dc.subject Solitary Fibrous Tumor en_US
dc.title The Role of Radiotherapy in Intracranial Hemangiopericytoma/Solitary Fibrous Tumors: a Turkish Society for Radiation Oncology Central Nervous System Tumors Group Study (trod 07-008) en_US
dc.type Article en_US

Files